Connect Biopharma appoints James A. Schoeneck to board of directors

Connect Biopharma Holdings Ltd

Board size increased from six to seven; Schoeneck appointed effective July 22, 2025.
Schoeneck is former CEO of Depomed (2011-2017) and BrainCells (2005-2011).
Currently serves as independent director and chairman at FibroGen and Calidi Biotherapeutics.
Board determined Schoeneck is independent under Nasdaq rules.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.